Antisoma gets QTDP grant for AS1413 development
Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel products for the treatment of cancer. The company has operations in London, UK and Cambridge, MA. Antisoma,
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.